Table 1 Characteristics of included studies
Study | Country | Study design | Random method | Blinding | Duration | Conventional diuretic | Treatment | Number of patients | Age (mean ± SD) | Sex (M/F) | Serum Sodium Concentration (mmol/L) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Dominique Guyader (2002) | Multicenter trail | RCT | NA | Double-blind | 1 d | N | palcebo | 5 | 55.6 ± 10.1 | 3/2 | 139.0 ± 3.2 |
VPA-985 25 mg | 4 | 58.5 ± 9.5 | 3/1 | 140.5 ± 2.1 | ||||||||
VPA-985 50 mg | 5 | 59.4 ± 6.0 | 5/0 | 135.7 ± 5.2 | ||||||||
VPA-985 100 mg | 4 | 61.2 ± 8.0 | 3/1 | 131.0 ± 6.0 | ||||||||
VPA-985 200 mg | 4 | 62.8 ± 5.8 | 3/1 | 139.0 ± 3.0 | ||||||||
VPA-985 300 mg | 5 | 49.0 ± 2.9 | 4/1 | 136.0 ± 2.1 | ||||||||
2 | Alexanderl. Gerbes (2003) | Multicenter trail | RCT | Computerized randomization | Double-blind | 7 d | NA | palcebo | 20 | 58 ± 2 | 15/5 | 127.3 ± 3.0 |
VPA-985 100 mg/d | 22 | 54 ± 3 | 17/5 | 128.3 ± 4.1 | ||||||||
VPA-985 200 mg/d | 18 | 56 ± 3 | 14/4 | 126.4 ± 4.4 | ||||||||
3 | Florence Wong (2003) | Multicenter trail | RCT | Computerized randomization | NA | 7 d | Y | palcebo | 8 | NA | NA | 127 ± 1 |
VPA-985 50 mg/d | 8 | 126 ± 1 | ||||||||||
VPA-985 250 mg/d | 10 | 122 ± 2 | ||||||||||
VPA-985 500 mg/d | 7 | 125 ± 1 | ||||||||||
4 | PJ THULUVAT H (2006) | USA | RCT | NA | Double-blind | 1 d | Y | palcebo | 6 | 50.5 ± 7.6 | 4/2 | 136 ± 2 |
RWJ-351647 1 mg | 6 | 56.5 ± 5.2 | 4/2 | 136 ± 5 | ||||||||
RWJ-351647 2 mg | 6 | 51.5 ± 7 | 5/1 | 137 ± 2 | ||||||||
RWJ-351647 5 mg | 6 | 48.3 ± 1.2 | 5/1 | 136 ± 3 | ||||||||
5 | Pere Gines (2008) | Multicenter trail | RCT | Computerized randomization | Double-blind | 14 d | Y | palcebo | 28 | 55 ± 10 | 22/6 | NA |
Satavaptan 5 mg/d | 28 | 57 ± 8 | 16/12 | |||||||||
Satavaptan 12.5 mg/d | 26 | 56 ± 9 | 19/7 | |||||||||
Satavaptan 25 mg/d | 28 | 59 ± 10 | 20/8 | |||||||||
6 | Florence Wong (2010) | Multicenter trail | RCT | Computerized randomization | Double-blind | 12 weeks | Y | palcebo | 36 | 60 ± 9 | 26/10 | 136 ± 4 |
Satavaptan 5 mg/d | 39 | 59 ± 9 | 32/7 | 133 ± 6 | ||||||||
Satavaptan 12.5 mg/d | 36 | 59 ± 9 | 28/8 | 135 ± 5 | ||||||||
Satavaptan 25 mg/d | 40 | 60 ± 11 | 29/11 | 134 ± 5 | ||||||||
7 | Pere Gines (2010) | Multicenter trail | RCT | Computerized randomization | Double-blind | 14 d | Y | palcebo | 35 | 58 ± 9 | 22⁄13 | 137 ± 3 |
Satavaptan 5 mg/d | 40 | 58 ± 9 | 30⁄10 | 137 ± 3 | ||||||||
Satavaptan 12.5 mg/d | 35 | 57 ± 8 | 26⁄9 | 136 ± 4 | ||||||||
Satavaptan 25 mg/d | 38 | 55 ± 9 | 25⁄13 | 136 ± 2 | ||||||||
8 | Andres Cardenas (2012) | USA | RCT | Stratified random | Double-blind | 30 d | Y | Placebo | 57 | 55 ± 9 | 38/19 | NA |
Tolvaptan 15-60 mg/d | 63 | 52 ± 8 | 50/13 | |||||||||
9a | Florence Wong (2012)a | Multicenter trail | RCT | Stratified random | Double-blind | 52 weeks | Y | placebo | 230 | 56.4 ± 9.2 | 168/62 | NA |
Satavaptan 5 or 10 mg/d | 232 | 56.6 ± 10.2 | 158/74 | |||||||||
9b | Florence Wong (2012)b | Multicenter trail | RCT | Stratified random | Double-blind | 52 weeks | Y | placebo | 168 | 57.0 ± 9.8 | 113/55 | NA |
Satavaptan 5 or 10 mg/d | 328 | 58.9 ± 10.0 | 237/91 | |||||||||
9c | Florence Wong (2012)c | Multicenter trail | RCT | Stratified random | Double-blind | 52 weeks | N | placebo | 80 | 56.2 ± 9.9 | 50/30 | NA |
Satavaptan 5 or 10 mg/d | 160 | 56.4 ± 9.6 | 108/52 | |||||||||
10 | Isao Sakaida (2014) | Japan | RCT | NA | Double-blind | 7 d | Y | placebo | 80 | NA | 49/31 | 135.7 ± 4.1 |
tolvaptan 7.5 mg/d | 82 | 52/30 | 135.3 ± 4.5 | |||||||||
11 | Kiwamu Okita (2014) | Japan | RCT | NA | Double-blind | 7 d | Y | placebo | 26 | 64 ± 10 | 17/9 | NA |
tolvaptan 7.5 mg/d | 25 | 65 ± 9 | 18/7 | |||||||||
tolvaptan 15 mg/d | 25 | 65 ± 10 | 21/4 | |||||||||
tolvaptan 30 mg/d | 25 | 63 ± 10 | 15/10 | |||||||||
12 | Pere Gines (2007) | Multicenter trail | RCT | NA | Single-blind | 52 weeks | Y | placebo | 47 | NA | NA | 132.5 |
satavaptan 5 mg/d-50 mg/d | 26 | 131.7 | ||||||||||
13 | Pere Gines (2008)’ | Multicenter trail | RCT | NA | Single-blind | 52 weeks | Y | placebo | 92 | NA | NA | NA |
satavaptan 5 mg/d-50 mg/d | 47 | |||||||||||
14 | Florence Wong (2009) | Multicenter trail | RCT | NA | Single-blind | 52 weeks | Y | placebo | 48 | NA | NA | NA |
satavaptan 5 mg/d-50 mg/d | 186 |